Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment
Pancreatic cancer has been termed a ‘recalcitrant cancer’ due to its relative resistance to chemotherapy and immunotherapy. This resistance is thought to be due in part to the dense fibrotic tumor microenvironment and lack of tumor infiltrating CD8 + T cells. The gastrointestinal peptide, gastrin, has been shown to stimulate growth of pancreatic cancer by both a paracrine and autocrine mechanism. Interruption of gastrin at the CCK receptor may reduce tumor-associated fibrosis and alter tumor immune cells. Polyclonal Ab Stimulator (PAS) is a vaccine that targets gastrin and has been shown to prolong survival of patients with pancreatic cancer. Here, we report that PAS vaccination monotherapy elicits both a humoral and cellular immune response when used in immune competent mice-bearing pancreatic tumors and that PAS monotherapy produced a marked T-cell activation and influx of CD8 + lymphocytes into pancreatic tumors. Isolated peripheral lymphocytes elicited cytokine release upon re-stimulation with gastrin in vitro demonstrating specificity of immune activation for the target peptide. Combination therapy with PAS and PD-1 Ab activated CD4 −/CD8 − TEMRA cells important in T-cell-mediated tumor death and memory. Tumors of mice treated with PAS (250 μg) or PAS (100 and 250 μg) in combination with a PD-1 Ab were significantly smaller compared to tumors from PBS or PD-1 Ab-treated mice. When PAS was given in combination with PD-1 Ab, tumors had less fibrosis, fewer inhibitory Treg lymphocytes, and fewer tumor-associated macrophages. These findings reveal a novel approach to improve treatment strategies for pancreatic cancer.
KeywordsTumor microenvironment Vaccine Gamma–delta T cells NKT cells Cellular immunity Gastrin
Polyclonal antibody stimulator
100 µg Polyclonal antibody stimulator
250 µg Polyclonal antibody stimulator
Pancreatic ductal adenocarcinoma
Terminally differentiated T cells
We appreciate the technical support from the staff in the Lombardi Georgetown Comprehensive Cancer Center Core Histology laboratory and Flow cytometry facilities. We also appreciate the staff in the animal care facility. All the investigations in this project were done at Georgetown University School of Medicine in the research laboratory of Dr. Smith, comparative medicine animal facility, and core labs (above) in the Lombardi Georgetown Comprehensive Cancer Center.
JPS, NO, RS, LS and AC conceived and designed research; JPS, JB, HC, and XL performed experiments; JPS, NO, RS, JB, HC, XL, AHK, LS and AC analyzed data; JPS, NO, RS, JB, HC, AHK, LS, and AC interpreted results of experiments; JPS, XL, and HC prepared figures; JPS drafted manuscript; NO, RS, JB, HC, XL, AHK, LS, AC, and JPS edited and revised manuscript; ALL authors approved the content of the final version of manuscript.
The study was funded in part by a grant from Cancer Advances, Inc. and its subsidiary Vaccicure, and NIH CA051008 to the Georgetown Lombardi Cancer center Core facilities.
Compliance with ethical standards
Conflict of interest
Cato Research, Durham NC has intellectual property rights for PAS. PAS compound was transferred to Georgetown University by a Material Transfer agreement with Vaccicure Limited, Liverpool, UK for this research project. All authors work for Cato Research or Georgetown University.
Ethical approval and ethical standards
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the Georgetown University. The IACUC Protocol Number was 2016-1193 and the protocol approval date was 10/05/2017.
C57BL/6 mice were purchased from Charles River Laboratories (Maryland).
Cell line authentication
Murine pancreatic cancer cells, mT3, were a gift from the Tuveson lab (Cold Spring Harbor, NY). Authentication of mT3 murine cells was performed by the investigator that developed the cells  and further IMPACT-III testing was performed by IDEXX BioResearch (Columbia, MO) to ensure the cells were pathogen-free.
- 1.Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617Google Scholar
- 4.Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30Google Scholar
- 11.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 Ab in patients with advanced cancer. N Engl J Med 366:2455–2465PubMedPubMedCentralGoogle Scholar
- 13.Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 Ab MPDL3280A in cancer patients. Nature 515:563–567PubMedPubMedCentralGoogle Scholar
- 15.Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW (2015) Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Ab) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293Google Scholar
- 17.Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, Denardo DG, Goedegebuure SP, Linehan DC (2016) Targeting tumour-associated macrophages with CCR17 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–662PubMedPubMedCentralGoogle Scholar
- 33.Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Ohlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324–338Google Scholar
- 36.Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E (2017) Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun 8:15221PubMedPubMedCentralGoogle Scholar
- 40.He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X (2019) CD8 + T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genom 18:99–106Google Scholar
- 41.Lohneis P, Sinn M, Bischoff S, Juhling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C, Oettle H, Blaker H, Riess H, Johrens K, Striefler JK (2017) Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:290–301PubMedGoogle Scholar
- 44.Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cance. J Clin Oncol 33:1325–1333PubMedPubMedCentralGoogle Scholar